BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma, Inc. (BBIO) announced that the FDA accepted its New Drug Application for oral infigratinib for children with achondroplasia with Priority Review and assigned a PDUFA target action date of February 4, 2027. BridgeBio anticipates a U.S. launch upon approval and intends to submit a Marketing Authorization Application to the EMA in the fourth quarter of 2026.
In PROPEL 3, the Phase 3 study met its primary endpoint at Week 52: the least-squares mean treatment difference in annualized height velocity was +1.74 cm/year, while the mean treatment difference was +2.10 cm/year (p<0.0001); the key secondary height Z-score endpoint also met (p<0.0001). In children ages 3–8, exploratory analyses reported a -0.05 mean difference in body proportionality (p<0.05); arm-span z-score was +0.37 SD (p<0.0001). The company reported favorable trends versus placebo in exploratory sleep apnea and otitis media endpoints.
BridgeBio Pharma, Inc. (BBIO) reported that Chief Executive Officer and director Neil Kumar had trusts associated with him sell a total of 10,000 shares of common stock on September 17, 2026, in open-market transactions under a Rule 10b5-1 sales plan adopted on May 13, 2026.
The Kumar Haldea Family Irrevocable Trust sold 8,721 shares at a weighted average price between $68.52 and $69.40 per share and 1,279 shares between $69.525 and $69.64 per share. Neil Kumar reports large remaining indirect holdings, including 3,568,447 shares via a revocable trust and 750,000 shares via the NK 2026 GRAT, plus 243,327 shares held directly, while disclaiming beneficial ownership of certain trust-held shares except for any pecuniary interest.
BridgeBio Pharma, Inc. (BBIO) announced a voluntary agreement with the U.S. government intended to expand access to its medicines and lower costs for American patients, particularly those with rare genetic diseases. As part of the agreement, BridgeBio plans to expand state Medicaid access to its currently marketed medicine via the GENEROUS Model, building on existing patient support programs such as ForgingBridges®, which can reduce qualifying patients’ out-of-pocket costs to as little as $0 per month.
BridgeBio states that it does not expect to be subject to future pricing mandates and that its pricing commitment for future medicines is expected to exclude products approved exclusively for orphan indications. The agreement does not affect coverage of Attruby through Medicare Part D or the ForgingBridges copay assistance program. The company also highlights three additional medicines under FDA review for rare genetic conditions, with priority review PDUFA dates in late 2026 and 2027.
BridgeBio Pharma, Inc. (BBIO) reported that Chief Executive Officer and director Neil Kumar filed a Form 4 disclosing open-market sales of a total of 44,980 shares of common stock on August 18–19, 2026. Some shares were sold directly and others were sold by the Kumar Haldea Family Irrevocable Trust, where he is a co‑trustee. The transactions were effected pursuant to a Rule 10b5-1 sales plan adopted on May 13, 2026, with reported weighted average sale prices in the low-to-mid $80s per share. After these transactions, separately reported indirect holdings include 3,568,447 shares held by the Kumar Haldea Revocable Trust and 750,000 shares held by the NK 2026 GRAT, with Kumar disclaiming beneficial ownership of certain trust-held shares except to the extent of his pecuniary interest.
BridgeBio Pharma, Inc. (BBIO) received a notice that the Kumar Haldea Family Irrevocable Trust plans to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares relate to a 03/26/2016 acquisition described as “Conversion Management Incentive Units.” A figure of $2,489,400.00 is listed for these 30,000 shares, and 195,487,474 common shares are shown as outstanding as of 08/19/2026 on NASDAQ. Over the prior three months, related 10b5‑1 sales are reported for Neil Kumar and related trusts, including multiple transactions of 20,000–34,980 shares of BBIO common stock with aggregate proceeds in the low‑ to mid‑million‑dollar range.
BridgeBio Pharma, Inc. (BBIO) reported that President and CFO Thomas Trimarchi had 22,781 shares of common stock withheld on August 16, 2026 to satisfy tax obligations related to the vesting of 41,194 RSU-based shares. After this tax-withholding disposition, he directly held 336,529 shares, which includes 116 shares acquired on August 14, 2026 through the company’s Employee Stock Purchase Plan.
BridgeBio Pharma, Inc. (BBIO) reported that its Chief Executive Officer, Neil Kumar, had 71,217 Restricted Stock Units (RSUs) convert into an equal number of shares of common stock on August 16, 2026. Corresponding RSU derivative positions were eliminated as the awards vested and settled into common shares.
To cover associated tax obligations from this vesting, 36,237 shares of common stock were delivered or withheld at a price of $79.86 per share. Following these transactions, indirect holdings reported include 515,686 shares held by the Kumar Haldea Family Irrevocable Trust, 3,568,447 shares held by the Kumar Haldea Revocable Trust, and 750,000 shares held by the NK 2026 GRAT, with the reporting person disclaiming beneficial ownership of these trust-held shares except to the extent of any pecuniary interest.
BridgeBio Pharma, Inc. (BBIO) reported that Chief Accounting Officer Maricel Apuli had 4,714 shares of common stock withheld on 2026-08-16 to satisfy tax obligations related to vesting of 9,262 RSU-based shares. After this tax-withholding disposition, Apuli directly holds 122,687 shares of BridgeBio common stock.
BridgeBio Pharma, Inc. (BBIO) received a notice that Neil Kumar intends to sell common stock under Rule 144. The filing lists 34,980 shares of common stock held through Morgan Stanley Smith Barney, with a reported value of $2,794,552.20, against 195,487,474 shares outstanding as of August 18, 2026. It also details prior Rule 10b5-1 plan sales over the past three months by Kumar and related trusts.
BridgeBio Pharma, Inc. common stock is the subject of this amended beneficial ownership report by KKR-affiliated entities. KKR Genetic Disorder L.P., as selling stockholder, entered into an underwriting agreement on August 13, 2026 with William Blair & Company, Goldman Sachs & Co. and KKR Capital Markets, covering an offering of 5,000,000 shares of common stock. The underwriters purchased these shares at a net price of $77.415 per share to KKR Genetic Disorder L.P., and the offering closed on August 17, 2026 under the issuer’s effective shelf registration.
After this transaction, KKR Genetic Disorder L.P. directly holds 8,260,971 shares of common stock, and the reporting group’s aggregate reported interest is 9,232,739 shares, including 971,768 shares issuable upon conversion or redemption of 133,900 shares of Series A Cumulative Convertible Participating Preferred Stock held by an alternative vehicle. This represents approximately 4.7% of BridgeBio’s common stock, based on 195,492,997 shares outstanding as of August 11, 2026, so the KKR reporting persons state they have ceased to be beneficial owners of more than five percent and characterize this amendment as an exit filing.